news

SilcsBio and Dalriada Drug Discovery Launch Partnership to Create a Rapid Drug Discovery Service Suite

SilcsBio and Dalriada Drug Discovery Launch Partnership to Create a Rapid Drug Discovery Service Suite

SilcsBio and Dalriada Drug Discovery Launch Partnership to Create a Rapid Drug Discovery Service SuiteJune 11, 2020SilcsBio and Dalriada to tap areas of expertise in drug design and development to accelerate clients’ programs in development of therapeutic treatments against diseases with unmet needs, initiated with COVID-19 FOR IMMEDIATE RELEASE: June 11, 2020,...

GEn1E Lifesciences, a Y Combinator-Backed Company, Granted Exclusive License for University of Maryland, Baltimore Drug Portfolio Compound

GEn1E Lifesciences, a Y Combinator-Backed Company, Granted Exclusive License for University of Maryland, Baltimore Drug Portfolio CompoundDecember 3, 2019PALO ALTO, Calif. and BALTIMORE, Dec. 3, 2019 /PRNewswire/ — GEn1E Lifesciences Inc., a Y Combinator-backed biotech startup focused on curing inflammatory and age-related diseases, announced today that it has acquired an exclusive, worldwide and...

SilcsBio, LLC Announces Release of CGenFF 2.3.0

SilcsBio, LLC Announces Release of CGenFF 2.3.0April 26, 2019Baltimore, MD, 26 April, 2019 – In ongoing efforts to improve the coverage of the CGenFF program, version 2.3.0 of the CGenFF program improves support for a variety of molecules via explicit parametrization of the molecules outlined below and...

SilcsBio, LLC Announces Release of CGenFF 2.1.0

SilcsBio, LLC Announces Release of CGenFF 2.1.0April 4, 2017Baltimore, MD, 4 March 2017 – In ongoing efforts to improve the coverage of the CGenFF program, version 2.1.0 of the CGenFF program extends support to the S-P bond found in the GTP-gamma like molecules. Bonded parameters and charge-distribution...